Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · April 20, 2021

Anti–SARS-CoV-2 Antibody Responses Are Attenuated in Infliximab-Treated IBD



Additional Info

Disclosure statements are available on the authors' profiles:

Anti–SARS-CoV-2 Antibody Responses Are Attenuated in Patients With IBD Treated With Infliximab
Gut 2021 May 01;70(5)865-875, NA Kennedy, JR Goodhand, C Bewshea, R Nice, D Chee, S Lin, N Chanchlani, J Butterworth, R Cooney, NM Croft, AL Hart, PM Irving, KB Kok, CA Lamb, JK Limdi, J Macdonald, DP McGovern, SJ Mehta, CD Murray, KV Patel, RC Pollok, T Raine, RK Russell, CP Selinger, PJ Smith, J Bowden, TJ McDonald, CW Lees, S Sebastian, N Powell, T Ahmad

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading